相关实验视频
Updated: Jun 15, 2025
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
9.8K
[二级肠道扩散型大B细胞淋巴瘤的临床特征和预后]
Xiao-Jun Chen1,2, Su-Xia Lin1, Dong-Hui Gan1
1Department of Hematology and Rheumatology, The Affiliated Hospital of Putian University, Putian 351100, Fujian Province, China.
Zhongguo shi yan xue ye xue za zhi
|August 27, 2024
概括
二次性肠扩散性大B细胞淋巴瘤 (SI-DLBCL) 主要影响中年男性,并呈现非特异性症状. 卢加诺阶段是SI-DLBCL患者整体生存期 (OS) 和无进展生存期 (PFS) 的关键独立预后因素.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床病理学 临床病理学
背景情况:
- 二次性肠扩散大B细胞淋巴瘤 (SI-DLBCL) 是一种罕见的恶性瘤,需要进一步调查其临床特征和预后.
- 了解预后因素对于改善罕见淋巴瘤的诊断和治疗策略至关重要.
- 以前对SI-DLBCL的研究是有限的,需要对临床特征和结果进行全面分析.
研究的目的:
- 分析二级肠扩散型大B细胞淋巴瘤 (SI-DLBCL) 的临床特征,治疗和预后因素.
- 为基础研究和罕见部位淋巴瘤的临床管理提供参考.
- 确定影响SI-DLBCL患者生存的独立预后因素.
主要方法:
- 对138名在福建医科大学联合医院接受治疗的SI-DLBCL患者的临床数据的回顾性分析 (2011年6月至2022年6月).
- 评估临床和病理特征,诊断,治疗方案和患者的结果.
- 考克斯回归模型的应用,用于预后风险因素的单变量和多变量分析.
主要成果:
- SI-DLBCL主要影响中年和老年男性 (61.59%),具有非特异性的临床表现.
- 主要的第一线治疗是化疗 (67.39%),主要是R-CHOP,单独的化疗是最常见的方法 (68.12%).
- 多变量分析确定了卢加诺阶段作为总生存期 (OS) 和无进展生存期 (PFS) 的独立预后因素.
结论:
- SI-DLBCL通常发生在中年到老年男性中,并且经常表现出模糊的早期症状.
- R-CHOP化疗是主要的第一线治疗,但卢加诺阶段显著影响患者的治疗结果.
- 卢加诺阶段是SI-DLBCL患者的OS和PFS的关键独立预后因素.
相关概念视频
01:30Inflammatory Bowel Disease II: Crohn's Disease
205
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
205
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
152
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
152
01:27Histology of the Small Intestine
589
The small intestine exhibits a unique histological structure that significantly enhances its function in digestion and nutrient absorption. These structures include circular folds, villi, and various specialized cells that collectively facilitate the digestion of food.
The intestinal lining features transverse folds called circular folds, each housing fingerlike projections known as intestinal villi. These villi are covered by a layer of simple columnar epithelium, also referred to as...
The intestinal lining features transverse folds called circular folds, each housing fingerlike projections known as intestinal villi. These villi are covered by a layer of simple columnar epithelium, also referred to as...
589
01:17Chronic Bowel Disorders: Introduction
420
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
420
01:15Secondary Lymphoid Organs
1.4K
Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
1.4K
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
159
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
159